Synthomer Utdelningar och återköp
Utdelning kriterier kontrolleras 0/6
Synthomer betalar för närvarande ingen utdelning.
Viktig information
0%
Avkastning på utdelning
n/a
Återköpsavkastning
| Total avkastning till aktieägarna | n/a |
| Framtida utdelningsavkastning | 0% |
| Utdelningstillväxt | n/a |
| Nästa utbetalningsdag för utdelning | n/a |
| Ex utdelningsdag | n/a |
| Utdelning per aktie | n/a |
| Utdelningsandel | 0% |
Senaste utdelnings- och återköpsuppdateringar
Inga uppdateringar
Recent updates
SYNT: Cost Actions And Bio-Based Shift Will Support Future Margin Stability
Analysts have slightly reduced their price expectations for Synthomer, reflecting updated assumptions for a less pronounced revenue decline, a small reduction in forecast profit margins, and a modest adjustment to future P/E. Taken together, these changes leave their fair value estimate unchanged at £0.59 per share.
SYNT: Cost Cuts And Bio Based Shift Will Support Future Upside
Analysts have nudged their price target on Synthomer slightly, reflecting modest tweaks to assumptions around discount rate, profit margin and future P/E, while keeping the underlying fair value estimate broadly unchanged at £1.27. What's in the News Godavari Biorefineries Limited entered a partnership with Synthomer to develop bio-based alternatives to existing fossil-based monomers, targeting growing customer demand for lower carbon and more sustainable materials (Key Developments).SYNT: Cost Actions And Bio-Based Partnership Will Support Future Margin Resilience
Analysts have adjusted their Synthomer price targets slightly to reflect updated views on revenue contraction, slightly higher profit margins, and a modestly lower future P/E, resulting in a revised fair value estimate of £0.59 per share. What's in the News Synthomer entered a partnership with Godavari Biorefineries Limited to develop bio-based alternatives to existing fossil-based monomers.SYNT: Cost Actions And Bio Based Shift Will Support Earnings Recovery
Analysts have trimmed their price target on Synthomer from £1.34 to about £1.27, citing updated assumptions on revenue growth, profit margins and future P/E multiples as they reassess the balance of risk and reward. What's in the News Godavari Biorefineries Limited partnered with Synthomer to develop bio-based alternatives to existing fossil-based monomers, including commercialisation of bio-based butyl acrylate using bio-based butanol from GBL, aimed at supporting customer demand for lower carbon materials (Key Developments).SYNT: Cost Actions And Bio-Based Shift Will Support Future Margin Resilience
Analysts have nudged their price target on Synthomer higher to £0.59. This reflects updated assumptions around slightly less severe revenue contraction and broadly unchanged profit margins and P/E expectations.SYNT: Cost Actions And Margin Resilience Will Support A Stable Fair Value View
Analysts have nudged their fair value estimate for Synthomer to £0.59 from £0.55, citing revised assumptions around revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Synthomer issued earnings guidance for the twelve months to 31 December 2025, with expected 2025 revenue of around £1.74b compared with £1.93b for 2024, described as in line with market expectations (Key Developments).SYNT: Earnings Prospects Will Stabilise As Fair Value View Remains Intact
Analysts have adjusted their price targets on Synthomer, reflecting revised assumptions around revenue growth, profit margins and future P/E multiples. Together, these changes point to a recalibrated view of the company’s earnings potential within an unchanged fair value estimate of £0.55 per share.SYNT: Self Help And 2026 Outlook Will Support Earnings Recovery
Analysts have trimmed their price expectations for Synthomer, with a lower fair value estimate and a reduced Street target to £1.02 from £1.12. This reflects updated views on revenue growth and earnings multiples while maintaining a broadly neutral stance on the shares.SYNT Will Face Mounting Pressure As Earnings Recovery Outlook Deteriorates
The analyst price target for Synthomer has been reduced to £1.02 per share from £1.12, as analysts factor in slower revenue growth assumptions, despite slightly higher profit margin expectations and a marginally increased discount rate. Analyst Commentary Recent research updates highlight a cautious stance from bearish analysts, who have progressively lowered their price targets on Synthomer as they reassess the company’s growth trajectory and risk profile.SYNT: Self-Help Actions Will Drive Earnings Recovery Despite Neutral Market Sentiment
Analysts have trimmed their price target on Synthomer slightly. This reflects a modest recalibration in fair value to approximately £1.34 per share following a series of recent target cuts that have reset expectations for the stock.SYNT: Full-Year Self-Help Actions Will Drive Earnings Recovery Momentum
Analysts have revised their price target for Synthomer downward from GBp 112 to GBp 102. This change is attributed to adjustments to future valuation metrics and an updated earnings outlook.SYNT: Future Gains Are Expected As End Markets Gradually Stabilize
Synthomer's analyst price target has been reduced from 112 GBp to 102 GBp. Analysts cite persistent end-market challenges and limited near-term prospects for earnings recovery as key factors behind the downward revision. Analyst Commentary Recent analyst coverage reflects a spectrum of perspectives regarding Synthomer's outlook, shaped by evolving market dynamics and the company's updated financial guidance.Future Earnings And Recovery Prospects Will Remain Under Pressure Amid Market Challenges
Synthomer's fair value estimate has been revised downward from £1.54 to £1.38 per share. Analysts cite ongoing challenges in end markets and modest growth prospects following the company's recent interim results.UK£1.57: That's What Analysts Think Synthomer plc (LON:SYNT) Is Worth After Its Latest Results
Aug 09
Sustainable Specialty Polymers Will Unlock New Global Opportunities
Despite a notable upgrade in revenue growth forecasts and a reduction in the forward P/E, Synthomer's consensus analyst price target has been revised down from £1.71 to £1.57. Valuation Changes Summary of Valuation Changes for Synthomer The Consensus Analyst Price Target has fallen from £1.71 to £1.57.
Chemical Realignment And Adhesives Expansion Will Build A Resilient Future
Shift to high-margin specialty chemicals and divestment of non-core operations are expected to enhance profitability.Investors Aren't Entirely Convinced By Synthomer plc's (LON:SYNT) Revenues
Jan 08Synthomer plc (LON:SYNT) Screens Well But There Might Be A Catch
Oct 05Calculating The Intrinsic Value Of Synthomer plc (LON:SYNT)
Aug 03Synthomer (LON:SYNT) Has Debt But No Earnings; Should You Worry?
Jun 18Investors Still Aren't Entirely Convinced By Synthomer plc's (LON:SYNT) Revenues Despite 27% Price Jump
May 25Is Synthomer plc (LON:SYNT) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 20Even With A 45% Surge, Cautious Investors Are Not Rewarding Synthomer plc's (LON:SYNT) Performance Completely
Mar 14Should You Think About Buying Synthomer plc (LON:SYNT) Now?
Feb 08Is Now An Opportune Moment To Examine Synthomer plc (LON:SYNT)?
Oct 17Here's Why Synthomer (LON:SYNT) Is Weighed Down By Its Debt Load
Sep 12Stabilitet och tillväxt i betalningar
Hämta utdelningsdata
Stabil utdelning: Otillräcklig data för att avgöra om SYNT s utdelningar per aktie har varit stabila tidigare.
Växande utdelning: Otillräcklig data för att avgöra om SYNT s utdelningsbetalningar har ökat.
Utdelningsavkastning jämfört med marknaden
| Synthomer Utdelningsavkastning jämfört med marknaden |
|---|
| Segment | Utdelningsavkastning |
|---|---|
| Företag (SYNT) | 0% |
| Marknadens lägsta 25% (GB) | 2.3% |
| Marknad Topp 25% (GB) | 5.7% |
| Genomsnitt för branschen (Chemicals) | 3.9% |
| Prognosanalytiker (SYNT) (upp till 3 år) | 0% |
Anmärkningsvärd utdelning: Det går inte att utvärdera SYNT s utdelningsavkastning mot de lägsta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.
Hög utdelning: Det går inte att utvärdera SYNT s utdelningsavkastning mot de översta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.
Vinstutdelning till aktieägarna
Resultattäckning: SYNT betalar ingen anmärkningsvärd utdelning för UK marknaden.
Kontantutbetalning till aktieägarna
Kassaflödestäckning: Det går inte att beräkna hållbarheten för utdelningar eftersom SYNT inte har rapporterat några utbetalningar.
Upptäck bolag med stark utdelning
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/03 09:45 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Synthomer plc bevakas av 21 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Katie Richards | Barclays |
| Robert Bate | Barclays |
| James Stewart | Barclays |